TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05739123: Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Sponsor: Sumitomo Pharma Switzerland GmbH · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 728 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT05739123 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05739123 Rescue Dossier →